EPIX Logo

ESSA Pharma Inc. (EPIX) 

NASDAQ
Market Cap
$79.64M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
208 of 774
Rank in Industry
121 of 432

Largest Insider Buys in Sector

EPIX Stock Price History Chart

EPIX Stock Performance

About ESSA Pharma Inc.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, …

Insider Activity of ESSA Pharma Inc.

Over the last 12 months, insiders at ESSA Pharma Inc. have bought $154,487 and sold $12.83M worth of ESSA Pharma Inc. stock.

On average, over the past 5 years, insiders at ESSA Pharma Inc. have bought $3.64M and sold $4.57M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BERGER FRANKLIN M (director) — $399,822. Parkinson David Ross (Chief Executive Officer) — $21,213.

The last purchase of 9,223 shares for transaction amount of $21,213 was made by Parkinson David Ross (Chief Executive Officer) on 2023‑12‑14.

List of Insider Buy and Sell Transactions, ESSA Pharma Inc.

2024-11-01Sale10 percent owner
7.88M
19.3487%
$1.53$12.02M+26.43%
2024-09-09SaleChief Operating Officer
694
0.0016%
$6.00$4,164+3.61%
2024-09-03SaleChief Operating Officer
2,082
0.0048%
$6.03$12,554+0.17%
2024-05-06SaleChief Operating Officer
694
0.0016%
$6.95$4,823-18.34%
2024-04-05SaleChief Operating Officer
694
0.0015%
$7.94$5,510-30.37%
2024-03-05SaleChief Operating Officer
694
0.0015%
$8.98$6,232-33.13%
2024-02-06SaleChief Operating Officer
72,782
0.2007%
$10.29$748,927-41.27%
2024-02-05SaleChief Operating Officer
1,194
0.0031%
$9.58$11,440-38.11%
2024-01-16SaleChief Operating Officer
1,718
0.0043%
$10.01$17,197-31.99%
2024-01-05SaleChief Operating Officer
699
0.0015%
$6.11$4,271+0.34%
2023-12-14PurchaseChief Executive Officer
9,223
0.0081%
$2.30$21,213+5.68%
2023-11-21Purchasedirector
23,259
0.0523%
$5.73$133,274+7.40%
2023-11-03Purchasedirector
16,471
0.0373%
$5.99$98,661+3.83%
2023-11-02Purchasedirector
60,000
0.1371%
$5.35$321,000+16.45%
2022-12-30PurchaseChief Executive Officer
3,067
0.0072%
$2.60$7,974+17.06%
2022-12-30PurchaseChief Financial Officer
8,302
0.0194%
$2.60$21,585+17.06%
2022-12-22PurchaseChief Executive Officer
21,367
0.0493%
$2.39$51,067+25.11%
2022-12-21Saledirector
72,223
0.1656%
$2.41$174,401+23.01%
2022-12-20Saledirector
43,617
0.0986%
$2.53$110,351+15.75%
2022-12-16Saledirector
50,000
0.1156%
$2.67$133,500+12.21%

Insider Historical Profitability

<0.0001%
BERGER FRANKLIN Mdirector
784404
1.7679%
$1.8045<0.0001%
Parkinson David RossChief Executive Officer
65675
0.148%
$1.8040+11.41%
BIOTECH GROWTH N V10 percent owner
0
0%
$1.8031<0.0001%
BB BIOTECH AG
5879583
13.2516%
$1.8021<0.0001%
Wood David S.Chief Financial Officer
33343
0.0751%
$1.8010+17.06%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bvf Inc Il$74.28M19.728.75M0%+$00.54
Bellevue Group$66.98M17.787.89M-0.11%-$76,410.001.03
Morgan Stanley$35.48M9.424.18M-0.19%-$68,174.70<0.01
Soleus Capital Management, L.P.$30.48M8.093.59M-17.05%-$6.27M0.13
PFM Health Sciences$25.3M6.722.98M-8.65%-$2.39M0.7
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.